Ecnoglutide

Research-Grade

Ecnoglutide (development code XW003) is a long-acting GLP-1 receptor agonist notable for its biased-agonism design. GLP-1 receptor activation can signal through multiple downstream routes, principally the cAMP/PKA second-messenger pathway and beta-arrestin recruitment. Ecnoglutide is engineered to preferentially activate cAMP signaling while minimizing beta-arrestin-mediated receptor internalization. The rationale is that cAMP signaling drives the metabolically beneficial effects — glucose-dependent insulin secretion and appetite regulation — while reduced receptor internalization may sustain surface receptor availability and improve the durability of the response. Structurally it is a modified human-GLP-1-based peptide with a fatty-acid modification for albumin binding and half-life extension, supporting once-weekly subcutaneous dosing. An oral formulation has also been pursued, positioning ecnoglutide among the agents attempting to broaden GLP-1 access beyond injectables. Ecnoglutide has been developed primarily in China, where it has progressed through Phase 2 and Phase 3 trials in type 2 diabetes and obesity. Reported results include dose-dependent HbA1c reductions and clinically meaningful weight loss, with a gastrointestinal tolerability profile typical of the class. It is not approved by the FDA, EMA, or MHRA and outside of clinical programs is treated as a research compound.